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The effects of intracerebroventricular (i. c.v.) application of a
somatostatin analogue, Octreotide, on growth of pituitary
adrenocorticotropes (ACTH cells) were examined in adult female
Wistar rats. The animals were subjected to i.e.v. administration of three
1.0 ~lg doses of Octreotide dissolved in 10 pi saline every second day.
Controls were treated in the same way with the same volume of saline.
ACTH-producing cells were studied using the peroxidase
-antiperoxidase (PAP) immunohistochemical procedure. Octreotide
treatment of rat females, significantly decreased (p <0.05) all
morphometric parameters measured, i.e. volume of ACTH cells and
their nuclei by 52% and 11%, respectively, as compared to the controls.
The volume densities were also significantly decreased (by 47%;
p<0.05) in comparison with the corresponding controls. These
findings suggest that centrally administered somatostatin analogue
(Octreotide) is specifically involved in the control of growth and
secretory activity of ACTH cells in female rats.
Key words: octreotide, pituitary, ACTH-cells, adrenocorticotropic
hormone, somatostatin, central nervous system, female rats.
INTRODUCTION
The neuropeptide somatostatin, widely expressed both in the periphery and
in the central nervous system (CNS) (Reichlin, 1983) has multiple functions in
higher organisms. It regulates endocrine and exocrine secretion, possesses
antiproliferative properties and acts as a neurotransmitter/neuromodulator
(Reubi, 1997). Two biologically active molecular forms deriving from a 116 amino
acid precursor have been characterized, the tetradecapeptide somatostatin-14
(SRIH-14) and the N-terminally extended form somatostatin-28 (SRIH-28) (Lewin
and LeRomancer, 1996). The diverse physiological effects are mediated by a
family of G-protein-coL!.pled cell surface receptors, the somatostatin receptors,
named sstr1 to sstr5 (Osapay, and Osapay, 1998). However clinical application
of either SRIH-14 or SRIH-28 has been limited because of their short half-life in
plasma (a few-minutes) (Sheppard et al., 1979).
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The first synthetic somatostatin analogue, known as Octreotide or
Sandostatin, synthesized by Bauer in February 1980 and consisting of 8 amino
acid residues (Bauer et al., 1982), was introduced for the treatment of
GH-secreting adenomas because of its longer half life (around 110 min) (Wass
1990) in comparison with SRIH-14 and SRIH-28. At present, Octreotide is in clinical
use for cancer therapy and gastrointestinal disorders and it was shown by
Scarpignato (1996) to interact primarily with the sstr2 receptor and was more
stable than native somatostatin.
In this report, the effects of intracerebroventricular (i.e.v.) Octreotide
administration on adrenocortical (ACTH) cells in adult female rats are
demonstrated by analysis of stereological parameters and immunocytochemical
properties.
MATERIAL AND METHODS
Animals
Adult Wistar female rats (200 - 220 g), maintained at the Institute for
Biological Research, Belqrade were used. They were kept under a 12:12 h
light-dark cycle, at 22 ± 2 DC. Feed (rat chow, a product of D.D.Veterinarski zavod,
Subotica,Yugoslavia) and tap water were available ad libitum.
Animal preparation
Surgical procedures were performed under ether anesthesia (aether ad
narcosis Ph. lug. III. produced by "Lek" Pharmaceutical Works, Ljubljana,
Slovenia). A headset implanted into the rats was used for i.c.v. injections. A
minimum recovery time of 5 days was permitted before initiation of the
experiments. The headset consisted of a silastic-sealed 20-gauge cannula
(Starcevic et aI., 1988), implanted into a lateral cerebral ventricle, 1 mm posterior
and 1.5 mm lateral to the bregma, and 3 mm below the cortical surface. A small
stainless steel anchor screw was placed at a remote site on the skull. The cannula
and screw were cemented to the skull with dental acrylic (Simgal; ICN Galenika,
Belgrade, Yugoslavia).
Treatment of animals
When recovered from surgical trauma the rats were divided into 2
experimental groups each consisting of five animals. Those from the first group
were given i.c.v.three 1flg doses of Octreotide (Sandoz, Switzerland) dissolved in
10 ~L1 saline with 48-h-intervals between the treatments. The second group, serving
as a control, was treated in the same way by the same time schedule with
physiological saline. All animals were sacrificed in deep anaesthesia by
decapitation 5 days after the last injection.
Light microscopy and immunocytochemistry
The pituitary glands were excised, fixed in Bourn-s solution for 48 hand
embedded in paraffin. Serialf-um thick tissue sections were deparaffinized in xylol
and serial alcohol. Pituitary hormones were localized by the peroxidase
-antiperoxidase complex (PAP) method of Stanberger et al. (1986). The
endogenous peroxidase activity was blocked by incubation in 9 mmol hydrogen
peroxide solution in methanol for 30 min at ambient temperature. Before the
application of the specific primary antiserum, nonspecific background staining
was achieved by incubating the sections with nonimmune, i.e. normal porcine
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serum diluted with phosphate buffered saline (PBS) pH 7.4, for 60 min. The
sections were then overlaid with the appropriate dilutions of the specific primary
antibodies (hACTH antiserum, Dako A/S, Glostrup, Denmark) for 24 h at 4 0C.
After washing in PBS, the sections were incubated for another 60 min with the
second antibody (swine-anti-rabbit IgG) for 45 min, rinsed again with PBS for 10
min and incubated with rabbit PAP serum for 45 min. Antibody localization was
visualized by incubating the sections in Tris-HCI-buffered saline (0.5 mol/I, pH 7.4)
supplemented with 3,3-diaminobenzidine tetrachloride (DAB, Serva, Heidelberg,
Germany) and 9 mmol/I hydrogen peroxide. Slides were thoroughly washed
under running tap water, counterstained with hematoxylin and mounted in Canada
balsam (Alkaloid, Skopje, FormerYug. Rep. of Macedonia). Control sections were
incubated without primary antisera or by substituting nonimmune rabbit serum for
the primary antiserum.
Morphometry
Volume densities (Vv) of both the nuclei and the cytoplasm of
ACTH-immuno-reactive cells, as well as numerical density (Na) of their nuclei per
~lm3 were measured using 50 test areas of the pituitary gland at a magnification
of X1 DOD, using the multipurpose test system M42 (Weibel, 1979).
The number of nuclei of immunoreactive ACTH-cells per mm3was estimated
applying the formula of Weibel and Gomez (1962) according to Weibel (1979).
Since rat ACTH cells are mononucleated, the numerical density of the nuclei (Nv)
corresponds to the number of cells per mm3:
Nv = (km) x (Na3/2Nv1/2)
On the basis of earlier karyometric studies of Malendowicz (1974), the shape
coefficient was estimated to be 1.382, for the pituitary cells. It relates Nv (number
of cells counted per volume unit) to Na (number of cells counted per mm3) and
Vv (volume density) and depends on the axial ratio of the nuclei.
Volume densities of the ACTH-positive cells were expressed as
percentages, taking total pituitary cells in flm3 as 100%.
Statistical analyses
Biochemical and morphometric data obtained from individual rats were
averaged per experimental group and the standard deviation of the mean was
calculated. A one-way analysis of variance (ANOVA), followed by the multiple
range test of Duncan (Pharmacological Calculation System, 1986) was used for
statistical comparisons between the groups. A probability value of 5% or less was
considered statistically significant.
RESULTS
Data on body weight, absolute and relative weight of the pituitary in the
Octreotide-treated group and in the corresponding control are summarized in
Table 1. Octreotide treatment did not lead to a significant change (p>0.05) of
these values in comparison with the controls.
The characteristic features of immunohistochemically labelled ACTH cells
in intact females are their localization between the capillaries and their stellate
shape with the cytoplasmic processes among neighbouring cells. The nucleus
follows the shape of the cell body. Small, specific secretory granules are
distributed mainly at the periphery of the cytoplasm as shown in -Fig. 1a. The
shape, and localization of ACTH immunoreactive cells in octreotide-treated female
rats was not significantly changed in comparison with the controls (Fig. 1b).
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Morphometric parameters measured in the present study, i.e. volume of
ACTH cells, their nuclei and volume density of these cells are presented in Fig.
2a, b, c. The mean volumes of ACTH cells and their nuclei were decreased in
Octreotide-treated females by 52% and 11%, respectively, in comparison with the
controls and the differences were statistically significant (p<0.05). The volume
density of ACTH in Octeotride-treated rat females was also significantly decreased
(by 47%; p<0.05) in comparison with control animals.
DISCUSSION
The results presented in this paper demonstrate, that repeated i.c.v. bolus
injections of Octreotide significantly decreased all morphometric and
immunocytochemical parameters of ACTH cells in adult female rats. Previously
reported data on the effects of somatostatin on ACTH-secreting cells are
somewhat conflicting (Richardson, 1981). Our earlier results (Starcevic et a!. 2000)
indicated that in contrast to 8RIH-14, i.c.v. administration of SRIH-28 to rat females
exerted significant inhibitory effects on the function and morphometric
charateristics of ACTH cells. We have also shown previously that i.c.v. treatment
of adult male rats with either SRIH-14 or SRIH-28 did not result in significant
changes of morphometric parameters of ACTH cells, or the blood concentration
of ACTH, when compared to the corresponding controls (Milosevic et aI., 1994;
Milosevic, 1999). These data could be connected with the report of Browen et al.
(1984) who demonstrated that SRIH-28 and 00T8-8S (an oligosomatostatin
analogue) given i.c.v. acted by inhibiting stress-induced pituitary ACTH secretion
in rats.
Octreotide primarily interacts with sstr2 and sstrs somatostatin receptor
subtypes and binds with a moderate affinity to sstr3 (Osapay and Osapay, 1998).
However, it expressed no affinity for binding to the sstr1 and sstr4 subtypes of this
receptor (Reisine and Ball, 1995). O,Carroll and Krempels (1995) found the mRNA
of all five somatostatin receptor subtypes (sstr1-5) in somatotrophs, thyreotrophs,
mammotrophs, corticotrophs and gonadotrophs. Octreotide was shown to inhibit
the adenylate cyclase system via type 2 somatostatin receptors (Patel and Srikant
1994).
The mechanism of inhibition of ACTH secretion was hypothesized by several
authors (Richardson, 1983; Browen et aI.,1984; Shibasaki et aI., 1988) to proceed
through the inhibition of CRF release from the hypothalamus. Also, Litvin et a!.
(1986) observed that SRIH inhibits CRF-induced ACTH secretion from At20 cells
in vitro. The action of SRIH was shown to be dose-dependent with a half-maximal
effect at 1x 10-9 M and to result in a reduced maximal ACTH secretion (Richardson,
1983). Octreotide may directly inhibit growth of SRIH receptor-positive tumours
by triggering signal transduction pathways that negatively control cell growth
(Hofland et aI., 1992). Indirect effects of Octreotide may involve suppression of
growth factors and hormones that stimulate tumor growth (Serri et a!., 1992).
In conclusion, our results indicate that i.c.v.-applied Octreotide, exerts
significant inhibitory effects on the immunohistochemical and morphometric
characteristics of ACTH cells in adult female rats. These data, together with the
reports of other authors, demonstrate that pharmacological manipulations of the
central somatostatin receptors employing compounds exerting binding affinity for
these receptors may provide a potent tool for altering ACTH physiology.
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EFEKTI OKTREOTIDA NA ACTH CELIJE HIPOFIZE ZENKI PACOVA
MILOSEVIC VERICA, BRKIC BRANISLAVA, NESTOROVIC NATASA, VELKOVSKI S i
STARCEVIC VESNA
SADRZAJ
Ispitivani su efekti intraeerebroventrikularno (i.e.v.) ubrizganog analoga
somatostatina, Oktreotida, na rast adrenokortikalnih (ACTH) celija adenohipofize
zenki Wistar paeova. Sve eksperimentalne zivotin]e su primile tri 1 ~lg doze
Oktreotida rastvorenog u 10 ul, tizioloskcq rastvora, svaki drugi dan. Kontrole su
tretirane na isti nacin fizioloskirn rastvorom. Paeovi su zrtvovani petog dana po
poslednjoj primljenoj dozi Oktreotida. ACTH celi]e su imunoeitohemijski bojene
PAP metodom. Dobijeni rezultati pokazuju da su statisticki znacajno smanjeni svi
morfometrijski parametri tretiranih zenki paeova u odnosu na odqovarajucu
kontrolu. Zapremina celija je smanjena za 52%, jedara za 11%, a volumenska
gustina za 47% (p<0.05) u poredjenju sa odqovarajucorn kontrolom. Na osnovu
dobijenih rezultata moze se zakljuciti za Oktreotid deluje inhibitorno na rast ACTH
celija adenohipofize zenki paeova.
